Article Information
PMID
Published By
Print ISSN
0250-7005
Online ISSN
1791-7530
History
- Received August 19, 2008
- Revision received December 11, 2008
- Accepted February 13, 2009
- Published online May 13, 2009.
Copyright & Usage
Copyright© 2009 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
Author Information
- SATOSHI OHNO1,2,3,
- SATOSHI DOHI1,
- YUMIKO OHNO1,
- SATORU KYO1,
- HARUO SUGIYAMA4,
- NOBUTAKA SUZUKI1,2 and
- MASAKI INOUE2
- 1Department of Obstetrics and Gynecology, Kanazawa University, Graduate School of Medical Science, Ishikawa
- 2Department of Complementary and Alternative Medicine Clinical R&D, Kanazawa University, Graduate School of Medical Science, Ishikawa
- 3International Research and Educational Institute for Integrated Medical Science, Tokyo Women's Medical University, Tokyo
- 4Department of Functional Diagnostic Science, Osaka University, Graduate School of Medicine, Osaka, Japan
- Correspondence to: Satoshi Ohno, Department of Complementary and Alternative Medicine Clinical R&D, Kanazawa University, Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8640 Japan. Tel: +81 762652147, Fax: +81 762344247, e-mail: satoshi.ohno55{at}gmail.com
Statistics from Altmetric.com
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Active Specific Immunotherapy Targeting the Wilms' Tumor Protein 1 (WT1) for Patients with Hematological Malignancies and Solid Tumors: Lessons from Early Clinical Trials
- Frequency of Myeloid Dendritic Cells Can Predict the Efficacy of Wilms' Tumor 1 Peptide Vaccination
- WT1 Peptide Vaccine Stabilized Intractable Ovarian Cancer Patient for One Year: A Case Report
- WT1 Expression Correlates with Angiogenesis in Endometrial Cancer Tissue
- Correlation between WT1 Expression and Cell Proliferation in Endometrial Cancer
- Wilms' Tumor 1 (WT1) Peptide Immunotherapy for Gynecological Malignancy